(MDGL) Madrigal Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 11.900m USD | Total Return: 63.5% in 12m

Stock Liver Drug, MASH Treatment, Thyroid Receptor
Total Rating 34
Risk 21
Buy Signal -0.19
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 11,900m
Avg Trading Vol: 127M USD
ATR: 5.04%
Peers RS (IBD): 49.3
Risk 5d forecast
Volatility58.9%
Rel. Tail Risk-11.6%
Reward TTM
Sharpe Ratio1.14
Alpha39.49
Character TTM
Beta1.126
Beta Downside1.657
Drawdowns 3y
Max DD61.41%
CAGR/Max DD0.49
EPS (Earnings per Share) EPS (Earnings per Share) of MDGL over the last years for every Quarter: "2021-03": -3.32, "2021-06": -3.72, "2021-09": -3.79, "2021-12": -3.78, "2022-03": -3.36, "2022-06": -4.14, "2022-09": -4.75, "2022-12": -4.98, "2023-03": -4.23, "2023-06": -4.69, "2023-09": -5.34, "2023-12": -5.68, "2024-03": -7.38, "2024-06": -7.1, "2024-09": -4.92, "2024-12": -2.71, "2025-03": -3.32, "2025-06": -1.9, "2025-09": -4.9555, "2025-12": -2.57, "2026-03": 0,
EPS CAGR: 22.11%
EPS Trend: 57.0%
Last SUE: 0.48
Qual. Beats: 0
Revenue Revenue of MDGL over the last years for every Quarter: 2021-03: 0.273, 2021-06: 0.01011, 2021-09: 0.008287, 2021-12: 3.732E-5, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.77, 2024-03: 0, 2024-06: 14.638, 2024-09: 62.175, 2024-12: 103.32, 2025-03: 137.25, 2025-06: 212.802, 2025-09: 287.268, 2025-12: 321.083, 2026-03: null,
Rev. CAGR: 1010.85%
Rev. Trend: 90.9%
Last SUE: 0.46
Qual. Beats: 0
Description: MDGL Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (MDGL) is a biopharmaceutical company specializing in treatments for metabolic dysfunction-associated steatohepatitis (MASH).

The companys primary product is Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for MASH. Biopharmaceutical companies typically invest heavily in research and development to bring new drugs to market, a process that can take many years.

Founded in 2016, Madrigal Pharmaceuticals is headquartered in West Conshohocken, Pennsylvania. Their business model focuses on developing and commercializing novel therapeutics for specific diseases, often involving a long regulatory approval process.

Further research on ValueRay can provide deeper insights into MDGLs financials and market position.

Headlines to Watch Out For
  • Rezdiffra sales drive core revenue growth
  • MASH treatment market competition intensifies
  • Regulatory approval for Rezdiffra in new regions
  • Clinical trial outcomes impact future pipeline valuation
  • Healthcare policy changes affect drug pricing and reimbursement
Piotroski VR‑10 (Strict, 0-10) 2.5
Net Income: -288.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.15 > 0.02 and ΔFCF/TA 29.24 > 1.0
NWC/Revenue: 97.61% < 20% (prev 479.5%; Δ -381.8% < -1%)
CFO/TA -0.15 > 3% & CFO -189.6m > Net Income -288.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.01 > 1.5 & < 3
Outstanding Shares: last quarter (22.4m) vs 12m ago 2.30% < -2%
Gross Margin: 94.14% > 18% (prev 0.96%; Δ 9.32k% > 0.5%)
Asset Turnover: 83.27% > 50% (prev 17.28%; Δ 65.99% > 0%)
Interest Coverage Ratio: -11.92 > 6 (EBITDA TTM -264.5m / Interest Expense TTM 22.3m)
Altman Z'' -5.43
A: 0.74 (Total Current Assets 1.25b - Total Current Liabilities 310.3m) / Total Assets 1.26b
B: -1.66 (Retained Earnings -2.09b / Total Assets 1.26b)
C: -0.23 (EBIT TTM -266.0m / Avg Total Assets 1.15b)
D: -3.18 (Book Value of Equity -2.09b / Total Liabilities 656.9m)
Altman-Z'' Score: -5.43 = D
Beneish M -0.25
DSRI: 0.47 (Receivables 134.5m/53.8m, Revenue 958.4m/180.1m)
GMI: 1.02 (GM 94.14% / 96.45%)
AQI: 1.29 (AQ_t 0.01 / AQ_t-1 0.00)
SGI: 5.32 (Revenue 958.4m / 180.1m)
TATA: -0.08 (NI -288.3m - CFO -189.6m) / TA 1.26b)
Beneish M-Score: -0.25 (Cap -4..+1) = D
What is the price of MDGL shares? As of April 02, 2026, the stock is trading at USD 523.47 with a total of 505,848 shares traded.
Over the past week, the price has changed by +14.70%, over one month by +21.63%, over three months by -10.78% and over the past year by +63.54%.
Is MDGL a buy, sell or hold? Madrigal Pharmaceuticals has received a consensus analysts rating of 4.47. Therefore, it is recommended to buy MDGL.
  • StrongBuy: 10
  • Buy: 3
  • Hold: 1
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the MDGL price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 668.6 27.7%
Analysts Target Price 668.6 27.7%
MDGL Fundamental Data Overview as of 02 April 2026
P/E Forward = 666.6667
P/S = 12.4168
P/B = 16.7917
Revenue TTM = 958.4m USD
EBIT TTM = -266.0m USD
EBITDA TTM = -264.5m USD
Long Term Debt = 339.9m USD (from longTermDebt, last quarter)
Short Term Debt = 1.02m USD (from shortTermDebt, last quarter)
Debt = 354.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 155.7m USD (from netDebt column, last quarter)
Enterprise Value = 11.27b USD (11.90b + Debt 354.4m - CCE 983.6m)
Interest Coverage Ratio = -11.92 (Ebit TTM -266.0m / Interest Expense TTM 22.3m)
EV/FCF = -59.32x (Enterprise Value 11.27b / FCF TTM -190.0m)
FCF Yield = -1.69% (FCF TTM -190.0m / Enterprise Value 11.27b)
FCF Margin = -19.83% (FCF TTM -190.0m / Revenue TTM 958.4m)
Net Margin = -30.08% (Net Income TTM -288.3m / Revenue TTM 958.4m)
Gross Margin = 94.14% ((Revenue TTM 958.4m - Cost of Revenue TTM 56.1m) / Revenue TTM)
Gross Margin QoQ = 92.39% (prev 93.69%)
Tobins Q-Ratio = 8.95 (Enterprise Value 11.27b / Total Assets 1.26b)
Interest Expense / Debt = 2.34% (Interest Expense 8.30m / Debt 354.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -210.1m (EBIT -266.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.01 (Total Current Assets 1.25b / Total Current Liabilities 310.3m)
Debt / Equity = 0.59 (Debt 354.4m / totalStockholderEquity, last quarter 602.7m)
 Debt / EBITDA = -0.59 (negative EBITDA) (Net Debt 155.7m / EBITDA -264.5m)
 Debt / FCF = -0.82 (negative FCF - burning cash) (Net Debt 155.7m / FCF TTM -190.0m)
 Total Stockholder Equity = 658.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.05% (Net Income -288.3m / Total Assets 1.26b)
RoE = -43.76% (Net Income TTM -288.3m / Total Stockholder Equity 658.8m)
RoCE = -26.63% (EBIT -266.0m / Capital Employed (Equity 658.8m + L.T.Debt 339.9m))
 RoIC = -23.67% (negative operating profit) (NOPAT -210.1m / Invested Capital 887.8m)
 WACC = 9.71% (E(11.90b)/V(12.25b) * Re(9.94%) + D(354.4m)/V(12.25b) * Rd(2.34%) * (1-Tc(0.21)))
Discount Rate = 9.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.55%
 [DCF] Fair Price = unknown (Cash Flow -190.0m)
 EPS Correlation: 57.00 | EPS CAGR: 22.11% | SUE: 0.48 | # QB: 0
Revenue Correlation: 90.91 | Revenue CAGR: 1.01k% | SUE: 0.46 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.41 | Chg7d=+0.000 | Chg30d=-1.748 | Revisions Net=-2 | Analysts=5
EPS current Year (2026-12-31): EPS=-5.78 | Chg7d=+0.000 | Chg30d=-8.130 | Revisions Net=+0 | Growth EPS=+54.6% | Growth Revenue=+55.0%
EPS next Year (2027-12-31): EPS=12.79 | Chg7d=+0.000 | Chg30d=-3.627 | Revisions Net=-1 | Growth EPS=+321.3% | Growth Revenue=+46.1%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
Additional Sources for MDGL Stock Fund Manager Positions: Dataroma · Stockcircle